Amplified in breast cancer 1 (AIB1) is a transcriptional coactivator for nuclear receptors and other transcription factors. AIB1 has an important role in malignancy of several cancers such as breast and prostate cancers. However, its involvement in human hepatocellular carcinoma (HCC) progression remains unclear. Here, we found that AIB1 protein was overexpressed in 23 of 34 human HCC specimens (68%). Down-regulation of AIB1 reduced HCC cell proliferation, migration, invasion, colony formation ability and tumorigenic potential in nude mice. These phenotypic changes caused by AIB1 knockdown correlated with increased expression of the cell cycle inhibitor p21
Introduction
Hepatocellular carcinoma (HCC) grows rapidly and frequently associates with vascular invasion, metastasis, recurrence and poor prognosis. HCC is the fifth most common human cancer and the third leading cause of cancer death worldwide (Farazi and DePinho, 2006) . The increase in world-wide incidence and the high mortality of HCC highlight the importance of understanding the molecular mechanisms that trigger the neoplastic transformation of hepatocytes and the progression of HCC. However, the molecular mechanisms responsible for HCC development have not been well defined.
Amplified in breast cancer 1 (AIB1/SRC-3/pCIP/ ACTR/RAC-3/TRAM-1) is a member of the steroid receptor coactivator (SRC) family that also contains SRC-1 (NcoA-1) and SRC-2 (GRIP1/TIF2) (Xu and Li, 2003; Xu et al., 2009) . AIB1 can interact with nuclear receptors such as estrogen receptor and androgen receptor (AR), as well as other transcription factors such as activator protein-1 (AP-1), nuclear factor-kB (NF-kB) and E2F1 to enhance their effects on target gene transcription (Anzick et al., 1997; Chen et al., 1997; Li et al., 1997; Torchia et al., 1997; Tan et al., 2000; Werbajh et al., 2000; Louie et al., 2004) . AIB1 was found to be amplified and overexpressed in 5-10% or 30-60% of breast cancer biopsies in separate studies (Anzick et al., 1997; Bouras et al., 2001) . Overexpression of AIB1 in transgenic mouse mammary glands causes a high incidence of spontaneous breast cancer (TorresArzayus et al., 2004) , whereas AIB1 deficiency impairs the insulin-like growth factor-I/Akt signaling pathway, inhibits cell proliferation and migration and significantly suppresses the mouse mammary tumor induced by oncogene H-ras or chemical carcinogen (Wang et al., 2000; Xu et al., 2000; Kuang et al., 2004 Kuang et al., , 2005 . These results indicate that AIB1 has a critical role in breast cancer initiation and progression. In addition, AIB1 is also overexpressed in human prostate cancer and its expression is correlated with increased cancer cell proliferation, survival, migration and invasiveness (Zhou et al., 2005; Yan et al., 2008) . Genetic ablation of AIB1 inhibits spontaneous prostate cancer progression in mice (Chung et al., 2007) , indicating that AIB1 has a role in promotion of prostate cancer progression. Several other studies showed that AIB1 is overexpressed in human colon, pancreas and stomach cancers and may contribute to the development of metastases (Sakakura et al., 2000; Henke et al., 2004; Xie et al., 2005) . These results indicate that AIB1 is a bona fide oncogene.
It has been reported that AIB1 amplification occurred in 23% of primary HCC, 41% of metastatic HCC and 60% of recurrent HCC (Wang et al., 2002) , suggesting a potential impact of AIB1 on HCC. However, the expression profile of AIB1 protein and the role of AIB1 in HCC progression remain unknown. In this study, we report that the expression of AIB1 protein is significantly increased in 68% of primary HCC samples. Downregulation of AIB1 in HCC cells decreased cell proliferation rate, cell migratory/invasive ability and oncogenic potential in vitro and in vivo. Accordingly, AIB1 knockdown markedly increased cell cycle inhibitor p21 Cip1/Waf1 expression and decreased the expression of phosphorylated Akt, proliferation marker proliferating cell nuclear antigen (PCNA) and MMP-9. In agreement with the results of in vitro experiments, upregulation of AIB1 in human HCC tissues positively correlated with the expression of PCNA and MMP-9. Taken together, our results show that AIB1 is an important mediator of HCC progression, and offers potential as a therapeutic target molecule for HCC treatment.
Results

AIB1 expression is frequently upregulated in human HCC tissues and cell lines
The expression levels of AIB1 protein in a set of 34 human HCC specimens were examined by western blot and immunohistochemistry. As determined by western blot analysis, levels of AIB1 protein were significantly upregulated in 23 HCC specimens versus the surrounding non-tumorous liver tissues (Figure 1a) . Immunohistochemical analyses of AIB1 in sections from paraffin-embedded HCC samples provided results consistent with that derived from western blot analysis ( Figure 1b and data not shown). In addition, AIB1 expression was also significantly increased in five HCC cell lines (HepG2, Huh7, Hep3B, SkHep1 and SMMC7721) when comparing with hepatocyte cell line L-O2 (Figure 1c) . Therefore, upregulation (-)   T  T  N  N  T  N  T  T  N  T  N  T  N  T   2  3  5  7  8   T  T  T  T  T  T  T  T  T  N  N  N  N  N  N  N  N  N   11  13  15  17   T  T  T  T  T  T  T  T  N  N  N  N  N  N  N  N   20  22  23  26   T  T  T  T  T  T  T  T  N 
Downregulation of AIB1 suppresses HCC cell proliferation
To investigate the role of AIB1 in HCC cell proliferation, RNA interference was used to knock down the expression of AIB1 in three HCC cell lines, HepG2, Huh7 and SK-Hep-1 and cell proliferation was measured by MTT assay. As shown in Figure 2a , AIB1-specific siRNA, but not control siRNA, efficiently reduced the levels of the endogenous AIB1 protein in these cells. Significantly, downregulation of AIB1 expression in these cells decreased cell proliferation at 96-120 h after AIB1-specific siRNA treatment , indicating that AIB1 is important for cell proliferation in a wide spectrum of HCC cells. To establish stable AIB1 knockdown cells for further study, HepG2 cells were stably transfected with pSU-PER (shCtrl) control vector or pSUPER-AIB1-shRNA (shAIB1) plasmid. Downregulation of AIB1 in shAIB1 stably transfected cells was confirmed by western blot analysis (Figure 2e, upper panel) . Similar to transient knockdown of AIB1 in HepG2 cells, stable knockdown of AIB1 in these cells resulted in a significant decrease in cell proliferation as measured by MTT assay as well as direct cell counting (Figures 2e and f) . Thereby, HepG2 Downregulation of AIB1 inhibits HCC cell cycle progression As downregulation of AIB1 resulted in a decrease in cell proliferation, cell cycle analysis was performed to examine whether AIB1 knockdown cells arrest in a specific phase of the cell cycle. Flow cytometric analysis showed that the percentage of AIB1 knockdown cells at G1 phase was increased by 15% as compared with control cells, and this was associated with a concomitant decrease of cells at the S and G2-M phases of the cell cycle ( Figure 3a ). In addition, the percentage of cells at sub-G1 phase, which represents apoptotic cells, was low and similar in both types of cells (Figure 3a) , indicating that downregulation of AIB1 does not significantly increase cell apoptosis under normal growth conditions. To understand the mechanisms underlying the changes in cell cycle progression, mRNA levels of several cell cycle-related genes were compared between control cells and AIB1 knockdown cells by using real time RT-PCR. Downregulation of AIB1 did not cause significant changes in the expression of Cyclin A1, Cyclin A2, Cyclin D1, Cyclin D3 and Cyclin E2 (data not shown), but resulted in a significant increase in the expression of the cell cycle inhibitor p21
Cip1/Waf1 and a concomitant decrease in the expression of the proliferation marker PCNA ( Figure 3b ). Consistent with changes in mRNA levels, AIB1 knockdown cells showed significantly increased protein levels of p21 Cip1/Waf1 and decreased protein levels of PCNA as measured by western blot analysis ( Figure 3c ). These results substantiate the promoting effect of AIB1 on HCC cell cycle progression. Downregulation of AIB1 is frequently associated with inhibition of Akt signaling (Zhou et al., 2003; Oh et al., 2004; Yan et al., 2006) , and inhibition of Akt signaling can lead to upregulation of the CDK inhibitor p21
Cip1/Waf1 (Thaler et al., 2009) . We therefore examined the effect of downregulation of AIB1 on the activation of Akt signaling by measuring the expression of phosphorylated Akt. Western blot analysis showed that the expression of phosphorylated Akt was significantly decreased in AIB1 knockdown cells (Figure 3c ), indicating that downregulation of AIB1 is able to inhibit Akt signaling, which in turn leads to upregulation of p21 Cip1/Waf1 expression and concomitant downregulation of PCNA expression. This notion was further supported by the results that p21
Cip1/Waf1 expression was increased but PCNA expression was decreased in HepG2 cells after treatment with the PI3K/Akt inhibitor LY294002 (Figures 3d and e) . Perhaps HepG2 cells already have high levels of AIB1 (Figure 1c ), a further increase of AIB1 expression by infection with AIB1-encoding lentivirus alone did not cause 
Downregulation of AIB1 reduces HCC cell migration and invasion
It has been reported that Akt can promote cancer cell migration and invasion via increased MMP-9 expression and AIB1 is involved in the migration and invasion of breast and prostate tumor cells (Kim et al., 2001; Qin et al., 2008; Yan et al., 2008) . Therefore, we hypothesized that downregulation of AIB1 may lead to a decrease in the migratory and invasive ability of HCC cells. To test this hypothesis, we investigated the migratory and invasive ability of AIB1 knockdown cells by using transwell cell migration and invasion assays. In the transwell migration assay, we found that downregulation of AIB1 decreased the ability of cells to migrate through the membrane (Figure 4a ). In the transwell invasion assay, We used 12-O-tetradecanoylphorbol-13-Acetate (TPA), an activator of protein kinase C that can promote HepG2 cell invasion via MMP-9 induction (Liang et al., 2009) , to induce cell invasion and found that downregulation of AIB1 significantly decreased the number of cells that penetrated through the Matrigel-coated membrane (Figure 4b ). These results indicate that the invasive potential of HCC cells is significantly reduced by AIB1 knockdown. In agreement with the reduced invasive potential of AIB1 knockdown cells, TPA-induced MMP-9 enzymatic activity was significantly decreased in the conditioned medium of AIB1 knockdown cells (Figure 4c ). To determine whether reduced MMP-9 enzymatic activity is resulted from the decreased mRNA Figure 4d , downregulation of AIB1 significantly decreased the mRNA levels of MMP-9 in TPA-treated cells, suggesting that AIB1 is required for TPA-induced MMP-9 activation in HepG2 cells. Furthermore, stable overexpression of MMP-9 partially rescued the ability of AIB1 knockdown cells to invade the Matrigel-coated membrane (Figures 4e and f) , indicating that AIB1 is a major mediator of MMP-9 induction. To examine whether the decreased levels of MMP-9 mRNA in TPA-treated AIB1 knockdown HepG2 cells was due to inhibition of de novo transcription of the mmp-9 gene, we examined the effects of AIB1 downregulation on the MMP-9 promoter activity by transient transfection assays using a MMP-9 promoter-luciferase reporter. After transfection of this reporter into HepG2 cells, the cells were treated with TPA for 24 h and luciferase activity was then determined. As shown in Figure 5a , MMP-9 promoter activity was decreased in AIB1 knockdown cells versus control cells. As both NF-kB and AP-1 are major regulators that activate the promoter of the mmp-9 gene (Sato and Seiki, 1993) , we examined the effects of downregulation of AIB1 on TPA-induced NF-kB and AP-1 transactivation. As shown in Figures 5b and c , downregulation of AIB1 reduced TPA-induced NFkB and AP-1 transactivation, respectively, indicating that AIB1 regulates MMP-9 expression at least in part through NFkB and AP-1. Furthermore, the results of ChIP assay showed that AIB1 was recruited to the MMP-9 promoter and the recruitment was reduced after knockdown of NF-kB (p65) and AP-1 (junB), respectively (Figure 5d ).
Downregulation of AIB1 inhibits HCC colony formation and tumorigenesis in nude mice
To assess the oncogenic potential of AIB1 in vitro, colony formation assay on the cell culture plate and anchorage-independent growth/colony formation assay in soft agar were performed. Downregulation of AIB1 significantly decreased colony formations in both assays (Figure 6a and Supplementary Figure 1) , showing that AIB1 enhances anchorage-independent growth and colony formation.
To further investigate the role of AIB1 in HCC progression, we assessed the effect of AIB1 knockdown on the growth of HCC xenograft tumors in nude mice injected with AIB1 knockdown cells or control cells. AIB1 knockdown HepG2 tumors grew much slower than control tumors (Figure 6b ). At the end of the study (day 28), tumor size of AIB1 knockdown group (120 ± 30 mm 3 ) was only 35% of the control group (340 ± 140 mm 3 ) (Figure 6c ). To correlate the biological response with the mechanisms identified in cells, PCNA protein was assessed by western blot analysis. As shown in Figure 6d , PCNA expression was significantly decreased in four representative AIB1 knockdown HepG2 tumors. These data indicate that AIB1 is able to promote HCC tumor growth in nude mice.
Upregulation of AIB1 enhances the expression of PCNA and MMP-9 in human HCC tissues To determine whether AIB1-regulated PCNA and MMP-9 expression in HCC cell lines and xenograft tumors has clinical implications, we assessed the (Figure 7c) . A positive correlation between levels of AIB1 protein and PCNA protein was identified in human HCC specimens (Figure 7d ). These data suggest that AIB1 may contribute to HCC growth. In agreement with the results from in vitro experiments, MMP-9 expression in AIB1-postive HCC was significantly higher than that in AIB1-negative HCC (Figure 7e ), suggesting that AIB1-postive HCC may have higher invasive capability. Enhanced tumor growth and invasion might lead to an earlier onset or diagnosis of the disease in patients with AIB1-positive HCC. Indeed, the average age of patients with AIB1-positive HCC at the time of diagnosis (50.6 ± 13.0 years old) is significantly lower than that of patients with AIB1-negative HCC (59.3±9.7 years old) (Figure 7f ). Strikingly, all patients under 45 years of age (nine cases, mean 39 ± 3.7 years old) developed AIB1-positive HCC.
Discussion
In this study, we found that the levels of AIB1 protein were significantly increased in 68% of primary HCC compared with surrounding non-tumorous liver tissue. 
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The most significant finding of this study is that AIB1 expression in HCC tissues is positively correlated with expression of the proliferation marker PCNA, indicating that AIB1 is a master regulator of human HCC growth. This notion is supported by the fact that knockdown of AIB1 causes the in vitro growth inhibition of three different HCC cell lines and the in vivo growth inhibition of HepG2 tumors in nude mice. Downregulation of AIB1 in HepG2 cells results in reduced cell proliferation, an arrest of the cell cycle in G0-G1 and a significant increase in the expression of cell cycle inhibitor p21 Cip1/Waf1 . The increase in p21
Cip1/Waf1 could, by inhibiting cyclin D1/cdk4 or cdk6 kinase activity (Sherr and Roberts, 1999) , block cell cycle progression. Several studies showed that upregulation of p21 Cip1/Waf1 inhibited HCC cell proliferation, and upregulation of p21
Cip1/Waf1 could be achieved by inactivation of JNK or the PI3K/Akt pathway (Hui et al., 2008; Thaler et al., 2009) . Indeed, we also observed that inhibition of PI3K/Akt pathway by a PI3 K inhibitor LY294002 enhanced p21 Cip1/Waf1 expression in HepG2 cells. These results indicate that downregulation of AIB1 reduces HCC cell proliferation at least in part through inactivating the Akt pathway and in turn, upregulating p21
Cip1/Waf1 expression. Surprisingly, no statistical difference in p21
Cip1/Waf1 expression between AIB1 positive HCCs and negative HCCs was observed in vivo (Supplementary Figure 2 ). The possible explanations for the observed discrepancy between in vitro and in vivo results are that other regulators of p21
Cip1/Waf1 (for example, p53, TGFb) may counteract the effects of AIB1 on p21 
As AIB1 is a coactivator for many nuclear receptors and other transcription factors including CREB, NF-kB, AP-1 and E2F1, the molecular mechanisms of AIB1 in promoting HCC progression are not limited to or entirely dependent on activation of Akt-signaling pathway or inhibition of p21
Cip1/Waf1 expression. For example, AIB1 can coactivate NF-kB and AP-1, two transcription factors involved in human HCC development. HCC is a malepredominant cancer associated with activation of AR (Ma et al., 2008) . As a coactivator for AR (Tan et al., 2000) , AIB1 is found to strongly coactivate AR in HCC cell lines (unpublished results). Therefore, AIB1 might promote HCC growth by enhancing the activation of different oncogenic pathways. This may partially explain the observations that AIB1 expression was positively correlated with the PCNA expression, but not necessarily with p21
Cip1/Waf1 expression. Invasion is a characteristic feature of HCC and a major poor prognostic factor in patients with HCC. Invasion of malignant HCC requires degradation of the extracellular matrix and the basement membrane. MMPs have an important role in the proteolytic destruction of extracellular matrix and basement membranes, they are therefore essential for tumor invasion. In breast cancer cells, AIB1 has been shown to activate MMP-2 and MMP-9 expression by serving as a coactivator for PEA3 and promote breast cancer invasion and metastasis (Qin et al., 2008) . MMP-9 has also been implicated in HCC invasion and metastasis and upregulation of MMP-9 can be achieved by activation of PI3K/Akt, NF-kB and AP-1 pathways (Sato and Seiki, 1993; Kim et al., 2001) . In this study, we have shown that AIB1 is able to enhance these oncogenic pathways in HCC cells. Therefore, AIB1 may enhance cell invasiveness by promoting MMP-9 expression both in vitro and in vivo via PI3K/Akt, NFkB and AP-1 pathways. Overexpression of stably transfected MMP-9 partially rescued the invasiveness of AIB1 knockdown cells, suggesting that although MMP-9 is a major downstream effector of AIB1 in regulating cell invasion, other invasion-related proteins such as Twist may also be involved (Kajiro et al., 2009) .
Activated Akt-signaling pathway is associated with high proliferation index, frequent intrahepatic metastasis and vascular invasion, advanced tumor stage and poor prognosis in HCC (Nakanishi et al., 2005) . The high labeling index of PCNA results in high risk of tumor recurrence, more aggressive growth and poor survival (Kitamoto et al., 1993) . MMP-9 gene is found to be highly expressed in HCC with invasive potential (Arii et al., 1996) . As AIB1 can activate abovementioned oncogenic events in HCC, elevated levels of AIB1 may be associated with tumor aggressiveness, high risk of tumor recurrence and poor prognosis in HCC. Therefore, AIB1 could be a potential predictor of poor prognosis of HCC patients after curative resection. It may also suggest that the optimal treatment scheme needs to be selected for patients with strong expression of AIB1 in HCC.
As in most cancers, multiple oncogenic pathways have been implicated in HCC progression. Therefore, simultaneous targeting of multiple oncogenic pathways is necessary for effective treatment of HCC. Indeed, sorafenib, a multikinase inhibitor against Raf-1, B-Raf, VEGFR2, PDGFR and c-Kit receptor, is the first agent that has shown an improved overall survival in patients with advanced HCC (Llovet and Bruix, 2008; . As overexpression of AIB1 in HCC can enhance the activation of multiple oncogenic pathways, therapeutic targeting AIB1 may dampen these oncogenic pathways simultaneously to achieve clinical benefit. Our studies reveal that RNA interference-mediated AIB1 gene silencing may serve as a therapeutic option for HCC treatment. In addition, Kajiro et al. (2009) recently reported that AIB1 is a direct target for ubiquitylation and degradation by a U-box-dependent E3 ubiquitin ligase CHIP (carboxyl terminus of Hsc70-interacting protein), suggesting that CHIP-mediated degradation of AIB1 may serve as another therapeutic approach for HCC treatment. Besides direct targeting AIB1, the cDNA microarray approach or proteomic analysis may enable us to compare the gene expression patterns between AIB1-positive and AIB1-negative HCC to identify novel AIB1-related targets for disease treatments.
In conclusion, our study highlights the crucial role of AIB1 in promoting the progression of human HCC by enhancing cell proliferation and invasiveness and suggests that modulation of AIB1 could represent a future therapeutic strategy for HCC.
Materials and methods
Tissue samples and cell lines
Tumorous and adjacent non-tumorous liver tissues were collected from 34 patients who underwent surgery for HCC at the First Affiliated Hospital of Xiamen University. Both tumor and non-tumorous tissues were confirmed histologically. Informed consent was obtained from each patient and the study protocol that conforms to the ethical guidelines of the 1975 Declaration of Helsinki was approved by the Institute Research Ethics Committee, Xiamen University. Human HCC cell lines HepG2, Hep3B, Huh-7, SK-Hep1, SMMC-7721 and hepatocyte cell line L-O2 were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin-streptomycin.
Plasmid construction
The À670 to þ 54 fragment of the MMP-9 promoter was inserted into the pGL3-basic vector to generate the pGL3-MMP-9-Luc promoter/reporter plasmid. AIB1-specific targeting sequence (19 nt sequences AGACTCCTTAGGACCGCTT of human AIB1 cDNA separated by a 9 nt spacer from the reverse complement of the same sequence) were cloned into pSUPER vector to generate pSUPER-shAIB1. MMP-9 cDNA was cloned into the mammalian expression vector pCR3.1 to generate pCR3.1-MMP-9. AIB1 cDNA was cloned into the lentiviral vector pBobi to generate pBobi-AIB1 for AIB1 expression.
Cell transfection and luciferase activity assays
The cells were transfected with reporter plasmids together with pCR3.1-Rluc as an internal control, in the presence or absence of pCR3.1-AIB1 plasmid by using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Cells were harvested 48 h posttransfection and luciferase activity was assayed and normalized to Renilla luciferase activity using a dual luciferase reporter assay system (Promega, Madison, WI, USA).
RNA interference and stable cell lines Target siRNAs and nonspecific siRNA were purchased from Dharmacon Inc. (Lafayette, CO, USA). siRNAs were transfected with INTERFERin siRNA transfection reagent (Polyplus Transfection, France) according to the manufacturer's instructions. To generate stably transfected cells, HepG 2 cells were transfected with pSUPER-shAIB1 and pSUPER control vector, respectively, and stably transfected cells were established by treatment with 1 mg/ml puromycin for 3 weeks.
Cell proliferation
Cell proliferation was analyzed by MTT assay. A total of 4 Â 10 3 cells were seeded in 96-well plates and MTT was added to each well every 24 h. The plates were incubated for 4 h before addition of solubilzation solution (10% SDS in 0.01 M HCl). The absorbance was measured at 560 nm using a microplate reader.
Cell cycle analysis
For cell cycle analysis, 8 Â 10 5 cells were synchronized by serum starvation for 24 h and induced to re-enter the cell cycle by an exchange of 10% fetal bovine serum for 24 h. Both floating and adherent cells were harvested and fixed in 75% ethanol at 4 1C overnight. Cells were incubated with RNase A at 37 1C for 30 min, and then stained with propidium iodide (PI). Cell cycle was measured by flow cytometry. The sub-G1 phase represents apoptotic cells.
Cell migration and invasion assays
Matrigel invasion assays were performed using Millicell inserts (Millipore, Billerica, MA, USA) coated with Matrigel (BD Biosciences, Sparks, MD, USA). 2.5 Â 10 4 cells were seeded per upper chambers in serum-free DMEM whereas the lower chambers were loaded with DMEM containing 5% FBS. After 24 h, the non-migrating cells on the upper chambers were removed by a cotton swab, and cells invaded through the matrigel layer to the underside of the membrane were stained and counted. Cell migration assays were performed similarly, but without Matrigel.
Gelatin zymography
Cells were seeded in a 12-well plate and cultured in serum-free DMEM with or without 100 nM TPA for 24 h. Conditioned medium was collected and subjected to electrophoresis on a 10% SDS-PAGE containing 1 mg/ml gelatin. The gels were washed in buffer I (50 mM Tris-HCl, pH 7.5 and 2.5% Triton X-100) for 30 min to remove SDS, incubated in buffer II (150 mM NaCl, 5 mM CaCl 2 , 50 mM Tris-HCl, pH 7.6, 0.02% NaN3) for 48 h. The gels were stained with 0.25% Coomassie brilliant blue and photographed.
Real-time reverse transcription (RT)-PCR
Total RNA was isolated with Trizol reagent (Invitrogen) according to the manufacturer's instructions. The cDNA was synthesized from 2 mg of total RNA using MMLV transcriptase (ToYoBo, Shanghai, China) with random hexamers. Real-time PCRs were performed using SYBR Premix ExTaq (TaKaRa, Dalian, China). Relative quantification was achieved by normalization to the amount of TBP. Primers used for real-time PCR are listed on Supplementary Table 1.
Western blot analysis
Equal amounts of protein lysates were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Filters were probed with the following specific primary antibodies: anti-AIB1 (provided by Wu R., Baylor College of Medicine), anti-p21
Cip1/Waf1 (BD Biosciences), PCNA (Abcam, Cambridge, MA, USA), b-actin (Sigma, St Louis, MO, USA), Akt and phosphorylated-Akt (Cell signaling, Danvers, MA, USA). Blots were then incubated with horseradish peroxidaseconjugated secondary antibody (Pierce, Rockford, IL, USA) and visualized by chemiluminescence. The band density was quantified by densitometry using Scion Image software and normalized to b-actin levels.
Immunohistochemistry
Immunohistochemistry was performed mainly as described (Yu et al., 2003) . Briefly, after antigen retrieval using microwave heating for 10 min, slides were washed and incubated with anti-AIB1 antibody (1:100) or anti-PCNA antibody (1:500) for 1 h followed by incubation with alkaline phosphatase-conjugated secondary antibody (Pierce) for 1 h. After washing, NBT/BCIP reagent was added to detect immunoreactive proteins.
Chromatin immunoprecipitation assay
HepG2 cells were used for ChIP and processed according to the method described by Abcam. The following primers were used: MMP-9 promoter sense strand 5 0 -GTCTTGCCTGACT TGGCAGT-3, antisense strand 5 0 -TGACAGGCAAGTGCT GACTC-3. Anti-SRC-3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Focus formation and soft agar assays
For focus formation assay, 500 cells were cultured in six-well plates in DMEM with 10% FBS. After 3 weeks, cells were stained with 0.005% crystal violet for 1 h to detect foci. For soft agar assay, cells were plated at a density of 5000 cells per well in 0.35% Noble agar-5% FBS-DMEM onto solidified 0.5% bed agar in DMEM with 10% FBS in 6-well plates. One ml of culture medium was added onto the top of solidified agar and changed every 3 days. After incubation for 21 days, colonies were stained with 0.005% crystal violet for 1 h. Colonies 4100 mm in diameter were counted.
Tumor xenografts
Four to six-week-old male nude mice were obtained from Laboratory Animal Center of Xiamen University. 4 Â 10 6 HepG2-shAIB1 cells and control cells were subcutaneously injected into the dorsal flanks of mice, respectively. From day 10 after cell injection, the size of the tumor was measured every 3 days by a vernier caliper along two perpendicular axes. The volume of the tumor was calculated following the formula: Volume ¼ Length Â Width 2 Â 0.52. Twenty-eight days after injection, the mice were killed and the tumors were photographed and used for western blot and immunohistochemical analysis. All experimental procedures involving animals were performed in accordance with animal protocols approved by Laboratory Animal Center of Xiamen University.
Statistical analysis
The data were collected from several independent experiments, with three replicates per experiment. All data were expressed as AIB1 regulates hepatocellular carcinoma progression Y Xu et al
